ALUR earnings analysis
What we found in ALUR's 10-Q: the parts that mattered, the offsets in the same document, and what the company said about what comes next.
Our reading of the filing · Free to read, no account needed
Allurion Technologies, Inc. reported a significant decline in revenue of 47% year-over-year, dropping to $2.9 million for Q1 2026. Despite a reduction in operating losses compared to the prior year, the company continues to face liquidity challenges due to its ongoing compliance issues with NYSE listing standards and the need for additional funding.
The parts that mattered.
Pulled out of the filing itself, with the figures the company reported.
- Revenue Decline of 47%
- Revenue fell to $2.9 million in Q1 2026 from $5.6 million in Q1 2025.
- Improved Operating Loss
- Operating loss decreased to $3.7 million from $7.3 million year-over-year.
- Increased Other Income
- Other income included a $4.3 million gain from changes in fair value of warrants.
- Reduced Cash Used in Operations
- Cash used in operating activities decreased to $3.2 million from $9.5 million year-over-year.
- Cash Position
- As of March 31, 2026, cash and cash equivalents were $5.1 million.
- FDA Approval Achieved
- Received PMA approval for the Allurion Gastric Balloon System on February 20, 2026.
And the other side of it.
The offsets in the same document — the things a summary that only listed the good news would have left out.
- NYSE Delisting Risk
- The company is under review for potential delisting due to failing to meet minimum market capitalization standards, risking its ability to trade publicly.
- Liquidity Concerns
- Ongoing losses and reliance on external funding pose risks to operational continuity.
- Sales and Marketing Restructuring Impact
- Shift in strategy towards B2B may negatively affect near-term revenue generation as direct customer sales decline.
What they reported.
What the company itself reported, taken out of the document.
- Earnings per share
- $-6.1
- Gross margin
- 41.7%
- Operating margin
- -126.6%
What they said about what is next.
Management does not provide specific numerical guidance; expects continued operating losses
The filing reads worse than the one before it.
What came before.
- 10-K · March 30, 2026
- Allurion reports a small, seasonal revenue base (approximately $16.0 million in 2025 from quarterly totals) and continues to commercialize its Allurion Program (200,000+ patients treated in 50+ countries). The company…
- 10-Q · November 17, 2025
- Allurion reported Q3 2025 revenue of $2,658,000 and a GAAP net loss of $11,884,000 (diluted EPS $(1.53)). Revenue and gross margin declined materially versus prior periods while operating expenses narrowed…
- 10-Q · May 15, 2025
- Allurion reported revenue of $5.58M for the quarter ended March 31, 2025, down materially from $9.39M a year earlier, while gross margin improved to 74.6%. The company generated net income of $7.38M but diluted EPS fell…
- 10-K · March 27, 2025
- Allurion positions itself as a platform play to "end obesity" with a Procedureless intragastric Allurion Balloon plus an AI-enabled Virtual Care Suite (VCS) and recently launched AllurionMeds. Clinically, the AUDACITY…
This is our reading of a public filing, not the filing. Read the original on SEC.gov · Educational only. Nothing here is investment advice.
Read the next one first.
We read every filing ALUR makes the day it lands, and put it next to what the options market did about it. Members get both, and an alert when a filing arrives.
Cancel anytime · Month to month · Switch tiers whenever